AbbVie Inc.
ABBV
Below: live stock price for AbbVie Inc. (ABBV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
AbbVie Inc. (ABBV) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 57,000 people. Over the past year ABBV traded between 190.75 and 281.29 USD. Trailing P/E sits near 79.41 on a market cap of about 496.77B USD. It currently yields 2.50% in dividends.
- Prev close
- $276.47
- Volume (24h)
- $1.54B
- Market cap
- $496.77B
- Currency
- USD
Score
48/ 100 · Mixed
- Value49
- Quality71
- Momentum47
- Growth72
- Risk73
- Dividend16
- Liquidity8
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 282.4026 +0.46%
- +20 bars
- 284.1818 +1.09%
- +60 bars
- 284.8731 +1.34%
- +120 bars
- 284.8985 +1.34%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0231 USD.
Interpretation
Composite signals look mixed. Strength: risk profile with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value49/100
Value looks mixed — driven by P/E (79.41).
P/E:79.41PEG:0.56 - Quality71/100
Quality looks solid — driven by Gross margin (72.79%).
ROA:10.51%Profit margin:9.80%Gross margin:72.79% - Momentum47/100
Momentum looks mixed — driven by 52w change (20.05%).
52w change:20.05% - Growth72/100
Growth looks solid — driven by Earnings growth (290.40%).
Revenue growth:10.20%Earnings growth:290.40% - Risk73/100
Risk looks solid — driven by Beta (0.23).
Beta:0.23Short interest:1.02% - Dividend16/100
Dividend looks fragile — driven by Payout ratio (190.40%).
Dividend yield:2.50%Payout ratio:190.40% - Liquidity8/100
Liquidity looks fragile — driven by Current ratio (0.81).
Current ratio:0.81Quick ratio:0.49
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 25.5%
- Max drawdown
- -16.5%
- Below period high
- -0.1%
- Best day
- +6.25%
- Worst day
- -5.20%
- Up days
- 51%
- Current streak
- 7 up
- Typical day swing
- 2.3%
- Volume vs average
- -3%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 281.29 high → 241.2 low · 60 bars
- ResistanceFib +161.8% extensionnot reached346.1556 USD+23.13% from current
- ResistanceFib +100% extensionnot reached321.38 USD+14.32% from current
- ResistanceFib +61.8% extensionnot reached306.0656 USD+8.87% from current
- ResistanceFib +27.2% extensionnot reached292.1945 USD+3.94% from current
- Current281.12 USD
- SupportFib 23.6% retracementNearesttested 3×271.8288 USD-3.31% from current
- SupportFib 38.2% retracementtested 17×265.9756 USD-5.39% from current
- SupportFib 50% midpointtested 18×261.245 USD-7.07% from current
- SupportFib 61.8% retracementtested 9×256.5144 USD-8.75% from current
- SupportFib 78.6% retracementtested 11×249.7793 USD-11.15% from current
- SupportFib −27.2% extensionnot reached230.2955 USD-18.08% from current
- SupportFib −61.8% extensionnot reached216.4244 USD-23.01% from current
- SupportFib −100% extensionnot reached201.11 USD-28.46% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $281.29
- 52w low
- $190.75
- 52w change
- 20.05%
- Day high
- $281.29
- Day low
- $276.01
- P/E (TTM)
- 79.41
- Forward P/E
- 17.29
- PEG
- 0.56
- Beta (5Y)
- 0.23
- Enterprise value
- 552.92B
- EV / Revenue
- 8.59
- EV / EBITDA
- 17.97
- EPS (TTM)
- $3.54
- Forward EPS
- $16.26
- Dividend yield
- 2.50%
- Dividend rate
- $6.92
- Payout ratio
- 190.40%
- Revenue (TTM)
- 64.39B
- EBITDA
- 30.76B
- Free cash flow
- 16.87B
- Total cash
- 6.57B
- Total debt
- 70.88B
- Current ratio
- 0.81
- Quick ratio
- 0.49
- Profit margin
- 9.80%
- Gross margin
- 72.79%
- Return on assets
- 10.51%
- Shares outstanding
- 1.77B
- Float
- 1.76B
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Analyst & Risk
- Beta (vs S&P 500)
- 0.23
- very stable
- 52-week change
- 20.05%
- Short % of float
- 1.02%
- Short ratio (days)
- 3.93
- Current ratio
- 0.81
- Quick ratio
- 0.49
- ROA
- 10.51%
- PEG ratio
- 0.56
- potentially undervalued
- EV / Revenue
- 8.59
- EV / EBITDA
- 17.97
- Revenue growth
- 10.20%
- Earnings growth
- 290.40%
- EBITDA
- 30.76B
- Free cash flow
- 16.87B
- Total cash
- 6.57B
- Total debt
- 70.88B
- Insider holdings
- 0.11%
- Institutional
- 77.33%
Recent rating changes
- 2026-10-09UBSNeutral → Neutralmain
- 2026-10-09GuggenheimBuy → Buyreit
- 2026-10-08JP MorganOverweight → Overweightmain
- 2026-10-08Cantor FitzgeraldOverweight → Overweightmain
- 2026-10-07Morgan StanleyOverweight → Overweightmain
- 2026-10-06ScotiabankSector Outperform → Sector Outperformmain
- 2026-09-10HSBCBuy → Buymain
- 2026-08-20Piper SandlerOverweight → Overweightmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-05
- Corporate Changes & Voting Matters8-K2026-09-03
- Corporate Changes & Voting Matters8-K2026-08-18
- Corporate Changes & Voting Matters8-K2026-08-05
- Periodic Financial Reports10-Q2026-08-03
- Corporate Changes & Voting Matters8-K2026-07-31
- Corporate Changes & Voting Matters8-K2026-07-06
- Annual report of employee stock purchase11-K2026-06-24
- Corporate Changes & Voting Matters8-K2026-06-22
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-06-01
- Corporate Changes & Voting Matters8-K2026-05-12
- Periodic Financial Reports10-Q2026-05-08
Recent news
- Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool4h ago
- Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?Zacks6h ago
- Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape24/7 Wall St.9h ago
- REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20PR Newswire9h ago
- SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASHStocktwits19h ago
- New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR Newswire1d ago
- 5 Dividend Stocks for Retirees Who Want More Than Just a Big Yield24/7 Wall St.1d ago
- AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.Motley Fool1d ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,462 USD-1.20%
- 7203.TToyota Motor Corporation2,910.5 USD+0.29%
- 9984.TSoftBank Group Corp.5,803 USD-3.92%
- 6758.TSony Group Corporation3,814 USD+2.91%
- 6861.TKeyence Corporation80,540 USD+0.68%
- NVDANVIDIA Corporation226.32 USD-1.29%
- AAPLApple Inc.340.97 USD+1.29%
- GOOGLAlphabet Inc.352.72 USD+0.30%
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.